Home / Going-concern warnings / Generate Biomedicines, Inc.
Filed 2026-05-07 路 Form 10-Q 路 Accession 0001193125-26-210059 small
Price before filing: $15.3 (2026-05-06 close, split/dividend-adjusted)
Market cap at flag: $1.74B (2026-05-07) 路 Latest: $1.55B (2026-10-16)
| Window | GENB | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -16.5% | +0.7% | -17.2% | 2026-06-08 |
| 90 days | -5.3% | +5.2% | -10.5% | 2026-08-05 |
| 180 days | pending | pending | until 2026-11-03 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 6 insiders bought $50.3M (7 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | AFEYAN NOUBAR (+6 joint filers) Director, 10% owner | Purchase | 1,562,500 | $16.00 | $25.0M | no | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR (+7 joint filers) Director, 10% owner | Purchase | 1,562,500 | $16.00 | $25.0M | no | Form 4 |
| 2026-03-02 | Grous Beth Chief People Officer | Purchase | 300 | $16.00 | $5K | no | Form 4 |
| 2026-03-02 | Mendillo Jane L Director | Purchase | 1,500 | $16.00 | $24K | no | Form 4 |
| 2026-03-02 | Silvers Jason President & CFO | Purchase | 500 | $16.00 | $8K | no | Form 4 |
| 2026-03-02 | Silvers Jason President & CFO | Purchase | 1,000 | $16.00 | $16K | no | Form 4 |
| 2026-03-04 | Nally Michael Chief Executive Officer, Director | Purchase | 20,000 | $12.00 | $240K | no | Form 4 |
| 2026-05-07: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-02-06 to 2026-06-06. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.